Syntheses and in vitro evaluation of arylsulfone-based MMP inhibitors with heterocycle-derived zinc-binding groups (ZBGs)
摘要:
Several classes of arylsulfone-based MMP-2/-9 inhibitors utilizing 6- to 8-membered heterocyclic rings as zinc-binding groups (ZBGs) have been synthesized and their enzyme inhibitory activities were evaluated. Although a number of 6- and 7-membered heterocycles were effective, the most potent arylsulfone inhibitors are based on the rigid 1- or 3-hydroxypyridone ZBG. (C) 2007 Elsevier Ltd. All rights reserved.
Syntheses and in vitro evaluation of arylsulfone-based MMP inhibitors with heterocycle-derived zinc-binding groups (ZBGs)
摘要:
Several classes of arylsulfone-based MMP-2/-9 inhibitors utilizing 6- to 8-membered heterocyclic rings as zinc-binding groups (ZBGs) have been synthesized and their enzyme inhibitory activities were evaluated. Although a number of 6- and 7-membered heterocycles were effective, the most potent arylsulfone inhibitors are based on the rigid 1- or 3-hydroxypyridone ZBG. (C) 2007 Elsevier Ltd. All rights reserved.
This invention provides novel heterocyclic derived matrix metalloprotease inhibitors of the formula:
and pharmaceutical compositions comprising same, useful for treating disorders ameliorated by antagonizing matrix metalloproteases. This invention also provides therapeutic and prophylactic methods using the instant pharmaceutical compositions.
[EN] HETEROCYCLIC DERIVED METALLOPROTEASE INHIBITORS<br/>[FR] INHIBITEURS HÉTÉROCYCLIQUES DE MÉTALLOPROTÉASES DÉRIVÉES
申请人:JANSSEN PHARMACEUTICA NV
公开号:WO2008045668A1
公开(公告)日:2008-04-17
[EN] This invention provides novel heterocyclic derived matrix metalloprotease inhibitors of the formula (I) and pharmaceutical compositions comprising same, useful for treating disorders ameliorated by antagonizing matrix metalloproteases. This invention also provides therapeutic and prophylactic methods using the instant pharmaceutical compositions. [FR] L'objet de la présente invention propose de nouveaux inhibiteurs hétérocycliques de métalloprotéases matricielles dérivées de formule (I) et des composés pharmaceutiques comprenant ces inhibiteurs, qui sont utiles pour traiter des troubles améliorés par des métalloprotéases matricielles antagonistes. Cette invention propose également des méthodes thérapeutiques et prophylactiques mettant en oeuvre les présentes compositions pharmaceutiques.
Syntheses and in vitro evaluation of arylsulfone-based MMP inhibitors with heterocycle-derived zinc-binding groups (ZBGs)
作者:Yue-Mei Zhang、Xiaodong Fan、Shyh-Ming Yang、Robert H. Scannevin、Sharon L. Burke、Kenneth J. Rhodes、Paul F. Jackson
DOI:10.1016/j.bmcl.2007.10.049
日期:2008.1
Several classes of arylsulfone-based MMP-2/-9 inhibitors utilizing 6- to 8-membered heterocyclic rings as zinc-binding groups (ZBGs) have been synthesized and their enzyme inhibitory activities were evaluated. Although a number of 6- and 7-membered heterocycles were effective, the most potent arylsulfone inhibitors are based on the rigid 1- or 3-hydroxypyridone ZBG. (C) 2007 Elsevier Ltd. All rights reserved.